Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5‐fluorouracil or carboplatin/paclitaxel for first‐line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck
Jimeno, Antonio, Machiels, Jean‐Pascal, Wirth, Lori, Specenier, Pol, Seiwert, Tanguy Y., Mardjuadi, Feby, Wang, Xiaodong, Kapp, Amy V., Royer‐Joo, Stephanie, Penuel, Elicia, McCall, Bruce, Pirzkall, Andrea, Clement, Paul M.
Published in Cancer (15.12.2016)
Published in Cancer (15.12.2016)
Get full text
Journal Article
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors
Nayak-Kapoor, Asha, Hao, Zhonglin, Sadek, Ramses, Dobbins, Robin, Marshall, Lisa, Vahanian, Nicholas N, Jay Ramsey, W, Kennedy, Eugene, Mautino, Mario R, Link, Charles J, Lin, Ray S, Royer-Joo, Stephanie, Liang, Xiaorong, Salphati, Laurent, Morrissey, Kari M, Mahrus, Sami, McCall, Bruce, Pirzkall, Andrea, Munn, David H, Janik, John E, Khleif, Samir N
Published in Journal for immunotherapy of cancer (20.06.2018)
Published in Journal for immunotherapy of cancer (20.06.2018)
Get full text
Journal Article
Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor
Ma, Shuguang, Suchomel, Julia, Yanez, Evelyn, Yost, Edward, Liang, Xiaorong, Zhu, Rui, Le, Hoa, Siebers, Nicholas, Joas, Lori, Morley, Roland, Royer‐Joo, Stephanie, Pirzkall, Andrea, Salphati, Laurent, Ware, Joseph A., Morrissey, Kari M.
Published in British journal of clinical pharmacology (01.08.2019)
Published in British journal of clinical pharmacology (01.08.2019)
Get full text
Journal Article
HER2 암 치료를 위한 병용 요법
DEY ANWESHA, SCHUTZMAN JENNIFER LEE, THANOPOULOU EIRINI, SONG CHUNYAN, WARBURTON SIMON PETER, JOO STEPHANIE ROYER, SONG KYUNG WHA
Year of Publication 11.08.2023
Get full text
Year of Publication 11.08.2023
Patent
고형 종양 치료를 위한 KRASG12C 억제제 및 EGFR-억제제를포함하는 방법 및 조성물
SCHUTZMAN JENNIFER LEE, MANDLEKAR SANDHYA VINAYAK, JOO STEPHANIE ROYER, EVANGELISTA MARIE, MERCHANT MARK ANDREW, LIN TING KUN MARK
Year of Publication 04.08.2023
Get full text
Year of Publication 04.08.2023
Patent
폐암 치료를 위한 KRASG12C 억제제 및 PD-L1 결합 길항제를 포함하는 방법 및 조성물
SCHUTZMAN JENNIFER LEE, MANDLEKAR SANDHYA VINAYAK, JOO STEPHANIE ROYER, EVANGELISTA MARIE, MERCHANT MARK ANDREW, LIN TING KUN MARK
Year of Publication 20.06.2023
Get full text
Year of Publication 20.06.2023
Patent
고형 종양 치료를 위한 KRASG12C 억제제 및 VEGF 억제제를 포함하는 방법 및 조성물
SCHUTZMAN JENNIFER LEE, MANDLEKAR SANDHYA VINAYAK, JOO STEPHANIE ROYER, EVANGELISTA MARIE, MERCHANT MARK ANDREW, LIN TING KUN MARK, LUTZKER STUART G
Year of Publication 20.06.2023
Get full text
Year of Publication 20.06.2023
Patent
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation
Sacher, Adrian, LoRusso, Patricia, Patel, Manish R., Miller, Wilson H., Garralda, Elena, Forster, Martin D., Santoro, Armando, Falcon, Alejandro, Kim, Tae Won, Paz-Ares, Luis, Bowyer, Samantha, de Miguel, Maria, Han, Sae-Won, Krebs, Matthew G., Lee, Jong-Seok, Cheng, Michael L., Arbour, Kathryn, Massarelli, Erminia, Choi, Yoonha, Shi, Zhen, Mandlekar, Sandhya, Lin, Mark T., Royer-Joo, Stephanie, Chang, Julie, Dharia, Neekesh V., Schutzman, Jennifer L., Desai, Jayesh
Published in The New England journal of medicine (24.08.2023)
Published in The New England journal of medicine (24.08.2023)
Get full text
Journal Article
Web Resource
An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer
Liu, Joyce, Burris, Howard, Wang, Judy S., Barroilhet, Lisa, Gutierrez, Martin, Wang, Yulei, Vaze, Anjali, Commerford, Renee, Royer-Joo, Stephanie, Choeurng, Voleak, Humke, Eric, Moore, Kathleen
Published in Gynecologic oncology (01.12.2021)
Published in Gynecologic oncology (01.12.2021)
Get full text
Journal Article
Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
Choi, Yoonha, Dharia, Neekesh V, Jun, Tomi, Chang, Julie, Royer-Joo, Stephanie, Yau, Kenneth K, Assaf, Zoe J, Aimi, Junko, Sivakumar, Smruthy, Montesion, Meagan, Sacher, Adrian, LoRusso, Patricia, Desai, Jayesh, Schutzman, Jennifer L, Shi, Zhen
Published in Clinical cancer research (03.09.2024)
Published in Clinical cancer research (03.09.2024)
Get full text
Journal Article
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
Desai, Jayesh, Alonso, Guzman, Kim, Se Hyun, Cervantes, Andres, Karasic, Thomas, Medina, Laura, Shacham-Shmueli, Einat, Cosman, Rasha, Falcon, Alejandro, Gort, Eelke, Guren, Tormod, Massarelli, Erminia, Miller, Wilson H., Paz-Ares, Luis, Prenen, Hans, Amatu, Alessio, Cremolini, Chiara, Kim, Tae Won, Moreno, Victor, Ou, Sai-Hong I., Passardi, Alessandro, Sacher, Adrian, Santoro, Armando, Stec, Rafal, Ulahannan, Susanna, Arbour, Kathryn, Lorusso, Patricia, Luo, Jia, Patel, Manish R., Choi, Yoonha, Shi, Zhen, Mandlekar, Sandhya, Lin, Mark T., Royer-Joo, Stephanie, Chang, Julie, Jun, Tomi, Dharia, Neekesh V., Schutzman, Jennifer L., Han, Sae-Won
Published in Nature medicine (2024)
Published in Nature medicine (2024)
Get full text
Journal Article
Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA -Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer
Jhaveri, Komal L., Accordino, Melissa K., Bedard, Philippe L., Cervantes, Andrés, Gambardella, Valentina, Hamilton, Erika, Italiano, Antoine, Kalinsky, Kevin, Krop, Ian E., Oliveira, Mafalda, Schmid, Peter, Saura, Cristina, Turner, Nicholas C., Varga, Andrea, Cheeti, Sravanthi, Hilz, Stephanie, Hutchinson, Katherine E., Jin, Yanling, Royer-Joo, Stephanie, Peters, Ubong, Shankar, Noopur, Schutzman, Jennifer L., Juric, Dejan
Published in Journal of clinical oncology (20.11.2024)
Published in Journal of clinical oncology (20.11.2024)
Get full text
Journal Article
Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer
Gerber, David E, Infante, Jeffrey R, Gordon, Michael S, Goldberg, Sarah B, Martín, Miguel, Felip, Enriqueta, Martinez Garcia, Maria, Schiller, Joan H, Spigel, David R, Cordova, Julie, Westcott, Valerie, Wang, Yulei, Shames, David S, Choi, YounJeong, Kahn, Robert, Dere, Randall C, Samineni, Divya, Xu, Jian, Lin, Kedan, Wood, Katie, Royer-Joo, Stephanie, Lemahieu, Vanessa, Schuth, Eva, Vaze, Anjali, Maslyar, Daniel, Humke, Eric W, Burris, 3rd, Howard A
Published in Clinical cancer research (15.01.2020)
Published in Clinical cancer research (15.01.2020)
Get full text
Journal Article
Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer
Moore, Kathleen N., Birrer, Michael J., Marsters, Jim, Wang, Yulei, Choi, YounJeong, Royer-Joo, Stephanie, Lemahieu, Vanessa, Armstrong, Katy, Cordova, Julie, Samineni, Divya, Schuth, Eva, Vaze, Anjali, Maslyar, Daniel, Humke, Eric W., Hamilton, Erika P., Liu, Joyce F.
Published in Gynecologic oncology (01.09.2020)
Published in Gynecologic oncology (01.09.2020)
Get full text
Journal Article
Abstract PS11-11: Targeted safety events from a phase I/Ib study evaluating GDC-0077 alone and in combination with endocrine therapy (ET) ± palbociclib (palbo) in patients (pts) with PIK3CA -mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC)
Olivera, Mafalda, Jhaveri, Komal, Juric, Dejan, Bedard, Philippe L, Cervantes, Andrés, Gambardella, Valentina, Hamilton, Erika, Italiano, Antoine, Kalinsky, Kevin, Krop, Ian E, Schmid, Peter, Turner, Nicolas, Varga, Andrea, Lei, Guiyuan, Royer-Joo, Stephanie, Thomas, Piia, Schutzman, Jennifer L, Saura, Cristina
Published in Cancer research (Chicago, Ill.) (15.02.2021)
Published in Cancer research (Chicago, Ill.) (15.02.2021)
Get full text
Journal Article
Long-term safety of inavolisib (GDC-0077) in an ongoing phase 1/1b study evaluating monotherapy and in combination (combo) with palbociclib and/or endocrine therapy in patients (pts) with PIK3CA -mutated, hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (BC)
Bedard, Philippe L., Accordino, Melissa Kate, Cervantes, Andres, Gambardella, Valentina, Hamilton, Erika P., Italiano, Antoine, Juric, Dejan, Kalinsky, Kevin, Krop, Ian E., Oliveira, Mafalda, Saura, Cristina, Schmid, Peter, Turner, Nicholas C., Varga, Andreea, Shankar, Noopur, Schutzman, Jennifer, Royer-Joo, Stephanie, Martin, Miguel Valero, Jhaveri, Komal L.
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
Abstract P5-17-05: A phase I/Ib study of inavolisib (GDC-0077) in combination with fulvestrant in patients (pts) with PIK3CA -mutated hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer
Juric, Dejan, Bedard, Phillippe L, Cervantes, Andrés, Gambardella, Valentina, Oliveira, Mafalda, Saura, Cristina, Kalinsky, Kevin M, Hamilton, Erika, Italiano, Antoine, Krop, Ian E, Schmid, Peter, Turner, Nicholas C, Varga, Andrea, Royer-Joo, Stephanie, Hutchinson, Katherine E, Schutzman, Jennifer L, Jhaveri, Komal L
Published in Cancer research (Chicago, Ill.) (15.02.2022)
Published in Cancer research (Chicago, Ill.) (15.02.2022)
Get full text
Journal Article
Abstract PS5-12: Preliminary correlative analysis of clinical outcomes with PIK3CA mutation (mut) status from a phase I/Ib study of GDC-0077 in patients (pts) with hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC)
Jhaveri, Komal, Juric, Dejan, Varga, Andrea, Turner, Nicolas, Schmid, Peter, Saura, Cristina, Oliveira, Mafalda, Krop, Ian E, Kalinsky, Kevin, Italiano, Antoine, Hamilton, Erika, Gambardella, Valentina, Cervantes, Andrés, Bedard, Philippe L, Liu, Bonnie P, Chen, Jessica W, Aimi, Junko, Royer-Joo, Stephanie, Schutzman, Jennifer L, Hutchinson, Katherine E
Published in Cancer research (Chicago, Ill.) (15.02.2021)
Published in Cancer research (Chicago, Ill.) (15.02.2021)
Get full text
Journal Article
Abstract PD1-02: A phase I/Ib study evaluating GDC-0077 + palbociclib (palbo) + fulvestrant in patients (pts) with PIK3CA -mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC)
Bedard, Philippe L, Jhaveri, Komal, Cervantes, Andrés, Gambardella, Valentina, Hamilton, Erika, Italiano, Antoine, Kalinsky, Kevin, Krop, Ian E, Oliveira, Mafalda, Saura, Cristina, Schmid, Peter, Turner, Nicolas, Varga, Andrea, Hutchinson, Katherine E, Lei, Guiyuan, Royer-Joo, Stephanie, Thomas, Piia, Schutzman, Jennifer L, Juric, Dejan
Published in Cancer research (Chicago, Ill.) (15.02.2021)
Published in Cancer research (Chicago, Ill.) (15.02.2021)
Get full text
Journal Article
Abstract CT109: A phase I/Ib study evaluating GDC-0077 plus fulvestrant in patients with PIK3CA -mutant, hormone receptor-positive/HER2-negative breast cancer
Kalinsky, Kevin, Juric, Dejan, Bedard, Philippe L., Oliveira, Mafalda, Cervantes, Andres, Hamilton, Erika, Krop, Ian E., Turner, Nick, Schmid, Peter, Varga, Andrea, Italiano, Antoine, Veitch, Zachary, Saura, Cristina, Gambardella, Valentina, Cheeti, Sravanthi, Kotani, Naoki, Lei, Guiyuan, Hutchinson, Katherine E., Royer-Joo, Stephanie, Vaze, Anjali, Schutzman, Jennifer L., Jhaveri, Komal
Published in Cancer research (Chicago, Ill.) (15.08.2020)
Published in Cancer research (Chicago, Ill.) (15.08.2020)
Get full text
Journal Article